A Randomized, Double-blind, Placebo-controlled Phase 1 Study of JMKX003948 Ophthalmic Suspension to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Dose(s) in Healthy Participants
Latest Information Update: 25 Feb 2025
At a glance
- Drugs JMKX 003948 (Primary)
- Indications Glioma; Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Jemincare
Most Recent Events
- 25 Feb 2025 New trial record